Shanghai Rixin Biotechnology

Shanghai Rixin Biotechnology is a clinical-stage biopharmaceutical company based in China, specializing in the development of targeted small molecule therapies for cancer. The company's core asset is RX-208 (also known as SKB208), a potent and selective BRAF V600E inhibitor designed to treat various solid tumors harboring the BRAF mutation. In 2021, the company was acquired by Sichuan Kelun-Biotech Biopharmaceutical, a move that integrated Rixin's oncology expertise and pipeline into Kelun-Biotech's extensive R&D infrastructure. Rixin's research focuses on addressing resistance mechanisms in targeted therapy and providing more effective treatment options for patients with specific genetic mutations. The company continues to advance its clinical programs under the Kelun-Biotech umbrella, targeting high-prevalence cancers in the Chinese market.